Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ:ATAI)

2.310 -0.010 (-0.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,666,918
Open 2.260
Bid (Size) 2.300 (5)
Ask (Size) 2.310 (2)
Prev. Close 2.320
Today's Range 2.180 - 2.330
52wk Range 1.030 - 2.565
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
atai Life Sciences to Participate in Upcoming Investor Conferences
From atai Life Sciences
Via GlobeNewswire
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more. 
Via Benzinga
Topics Government
Exposures Political

Performance

YTD
+44.4%
+44.4%
1 Month
+58.2%
+58.2%
3 Month
+26.9%
+26.9%
6 Month
+37.5%
+37.5%
1 Year
+39.2%
+39.2%

More News

Read More
Atai Life Sciences Stock Soars To 3-Month High As Depression Study Yields Promising Results: Retail Bulls Cheer
Via Stocktwits
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
DOD to Invest $9.8m into Psychedelic Studies Targeting Active-Duty Soldiers
Via Investor Brand Network
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Study Finds That Bad Psychedelic Trips Double Some Individuals’ Fatality Risk
Via Investor Brand Network
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
From atai Life Sciences
Via GlobeNewswire
Veterans Turn to One Another for Help Using Psychedelics to Combat Mental Health Challenges
Via Investor Brand Network
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months
Via Stocktwits
Trade Desk Posts Downbeat Revenue, Joins Aspen Aerogels, Fastly And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
Via Benzinga
atai Life Sciences Announces Pricing of Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
Wondering what's happening in today's after-hours session?
Via Chartmill
atai Life Sciences Announces Proposed Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
From atai Life Sciences
Via GlobeNewswire
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
Via Investor's Business Daily
Topics Government
Exposures Political
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
Via Benzinga
Exposures Product Safety

Frequently Asked Questions

Is ATAI Life Sciences N.V. - Common Shares publicly traded?
Yes, ATAI Life Sciences N.V. - Common Shares is publicly traded.
What exchange does ATAI Life Sciences N.V. - Common Shares trade on?
ATAI Life Sciences N.V. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for ATAI Life Sciences N.V. - Common Shares?
The ticker symbol for ATAI Life Sciences N.V. - Common Shares is ATAI on the Nasdaq Stock Market
What is the current price of ATAI Life Sciences N.V. - Common Shares?
The current price of ATAI Life Sciences N.V. - Common Shares is 2.310
When was ATAI Life Sciences N.V. - Common Shares last traded?
The last trade of ATAI Life Sciences N.V. - Common Shares was at 05/30/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.